OPTI Optibiotix Health Plc

TIDMOPTI

RNS Number : 9036D

OptiBiotix Health PLC

01 July 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")

LP(LDL) (R) license agreement with Kappa Bioscience AS for vascular health product

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a license agreement with Kappa Bioscience AS ("Kappa") for the use of Lactobacillus plantarum LP(LDL) (R) in a new application area within cardiovascular health. The agreement covers 27 countries, largely in Europe, but also includes Russia and Singapore.

The new vascular health product will combine ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LP(LDL) (R) ("LP(LDL) (R) ") with Kappa's proprietary K2VITAL(R) which they market as the purest and most active form of vitamin K2. The product is being developed to improve vascular health and is another addition to a portfolio of cardiovascular health products (cholesterol reduction, hypertension reduction) containing LP(LDL) (R). ProBiotix's preferred development and production partner, Nutrilinea Srl. in Milan (Italy), will cover the costs of development and will be the manufacturer of the final product. Kappa and ProBiotix will commercialise the product leveraging their existing and new distribution networks.

Based in Norway, Kappa has developed a technology to manufacture vitamin K2 MK-7 (all-trans menaquinone-7) with the highest purity and bioavailability, allowing for more cost-effective and efficacious dosing. Marketed under the K2VITAL(R) brand name through a global network of distributors K2VITAL(R) is amongst the most widely recognised brands of vitamin K2.

The product is being developed to optimise the complementary modes of action in both companies branded ingredients (LP(LDL) (R) and K2VITAL(R)) to reduce a number of independent cardiovascular risk factors. Calcification of blood vessels reduces their elasticity leading to arterial hardening which in turn increases cardiovascular disease morbidity and mortality. LP(LDL) (R) lowers cholesterol and blood pressure mitigating these predisposing factors whilst K2VITAL(R) keeps calcium in the bones and away from the blood vessels improving vascular health. The combination of both ingredients creates a product which has the potential to reduce a number of independent cardiovascular risk factors and improve cardiovascular health.

This agreement is a strategic step to include LP(LDL) (R) in a wide range of cardiovascular health supplements, and in food, dairy, and beverage products across the world. This builds brand recognition, enhancing brand value, and creates a demand by partners to include LP(LDL) (R) as the functional ingredient in a wider range of products.

Dr. Luis Gosalbez, Business Development Director of OptiBiotix, commented: "We are delighted to announce this deal with Kappa which will combine two clinically proven branded ingredients (LP(LDL) (R) and K2VITAL(R)) into a unique formulation designed to reduce a number of independent cardiovascular risk factors. This broadens the use of LP(LDL) (R) beyond cholesterol reduction and creates new market opportunities in the field of cardiovascular health. The result is a new product for vascular health, a segment of cardiovascular care where very few products are currently available. This increases brand recognition and value in addition to creating a demand for LP(LDL) (R) as an ingredient. This means we are able to derive revenue from both the sale of a wide range of cardiovascular health products containing LP(LDL) (R), as well as LP(LDL) (R) ingredient sales."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                             www.optibiotix.com 
 Stephen O'Hara, Chief Executive                 Contact via Walbrook 
                                                                below 
 
 Cairn Financial Advisers LLP (NOMAD) 
 Liam Murray / Jo Turner / Ludovico Lazzaretti     Tel: 020 7213 0880 
 
   finnCap (Broker) 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne      Tel: 020 7220 0500 
  (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 goetzpartners securities Limited                  Tel: 020 3859 7725 
 Ulrich Kinzel 
 Brigitte de Lima 
 
 Walbrook PR Ltd                                   Mob: 07876 741 001 
 Anna Dunphy 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGRBUGDLRDDBGCI

(END) Dow Jones Newswires

July 01, 2019 02:00 ET (06:00 GMT)

Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024